Jaguar Health, Inc. reported its consolidated financial results for the second quarter of 2025, revealing significant growth in net revenue. The company's combined net revenue for prescription products, including Mytesi®, Gelclair®, and Canalevia®-CA1, reached approximately $2.9 million, marking an increase of around 36% compared to the first quarter of 2025, which stood at approximately $2.2 million. This represents a 10% increase over the second quarter of 2024, where the net revenue was approximately $2.7 million. The overall net revenue for both prescription and non-prescription products, including license revenue, amounted to approximately $3.0 million, reflecting a 35% rise from the first quarter of 2025 and a 10% increase from the second quarter of the previous year. Additionally, Mytesi prescription volume grew by about 6.5% in the second quarter of 2025 over the preceding quarter, maintaining the same level as in the second quarter of 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.